NCT00002052

Brief Summary

To compare the effectiveness of standard treatment with parenteral ampicillin and oral amoxicillin compared to initial daily therapy with ceftriaxone followed by 3 times weekly suppressive treatment for salmonella infections in AIDS patients.

Trial Health

80
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

November 2, 1999

Completed
1.8 years until next milestone

First Posted

Study publicly available on registry

August 31, 2001

Completed
Last Updated

June 24, 2005

Status Verified

August 1, 1989

First QC Date

November 2, 1999

Last Update Submit

June 23, 2005

Conditions

HIV InfectionsSalmonella Infections

Keywords

Salmonella InfectionsAIDS-Related Opportunistic InfectionsAcquired Immunodeficiency SyndromeAmoxicillinCeftriaxone

Interventions

Ceftriaxone sodiumDRUG
Ampicillin sodiumDRUG
Amoxicillin trihydrateDRUG

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may not qualify if:

  • Co-existing Condition:
  • Patients with the following are excluded:
  • Type I hypersensitivity to beta-lactam antibiotics.
  • Not expected to survive 12 weeks.
  • In a coma or with other central nervous system (CNS) impairment.
  • Patients with the following are excluded:
  • Type I hypersensitivity to beta-lactam antibiotics.
  • Not expected to survive 12 weeks.
  • In a coma or with other central nervous system (CNS) impairment.
  • Prior Medication:
  • Excluded within 48 hours of study entry:
  • Treatment with an antibiotic active in vitro against Salmonella.
  • HIV infection, AIDS, or AIDS related complex (ARC).
  • Salmonella bacteremia or positive stool culture in patient with 3 or more stools per day.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Los Angeles County - USC Med Ctr

Los Angeles, California, 90033, United States

Location

MeSH Terms

Conditions

HIV InfectionsSalmonella InfectionsAIDS-Related Opportunistic InfectionsAcquired Immunodeficiency Syndrome

Interventions

CeftriaxoneAmpicillinAmoxicillin

Condition Hierarchy (Ancestors)

Blood-Borne InfectionsCommunicable DiseasesInfectionsSexually Transmitted Diseases, ViralSexually Transmitted DiseasesLentivirus InfectionsRetroviridae InfectionsRNA Virus InfectionsVirus DiseasesGenital DiseasesUrogenital DiseasesImmunologic Deficiency SyndromesImmune System DiseasesEnterobacteriaceae InfectionsGram-Negative Bacterial InfectionsBacterial InfectionsBacterial Infections and MycosesOpportunistic InfectionsSlow Virus Diseases

Intervention Hierarchy (Ancestors)

CefotaximeCephacetrileCephalosporinsbeta-LactamsLactamsAmidesOrganic ChemicalsThiazinesSulfur CompoundsHeterocyclic Compounds, 2-RingHeterocyclic Compounds, Fused-RingHeterocyclic CompoundsPenicillin GPenicillins

Study Design

Study Type
interventional
Phase
not applicable
Purpose
TREATMENT
Sponsor Type
OTHER

Study Record Dates

First Submitted

November 2, 1999

First Posted

August 31, 2001

Last Updated

June 24, 2005

Record last verified: 1989-08

Locations

US(1)